Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe 0.25mg starting dose of Wegovy (semaglutide) has a half-life of roughly seven days, meaning it takes around five weeks for a single dose to leave your system almost entirely. Because it is given weekly and builds up, the drug reaches steady-state levels in blood after approximately four to five weeks of consistent dosing. That pharmacokinetic profile shapes when effects — and side effects — are felt most. Wegovy is a prescription-only medicine; a prescriber assesses whether it is suitable for you before any dose is issued.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The pen arrives in a plain, unbranded DPD box, the tracking notification on your phone is often the first sign it's there. Inside is the pre-filled semaglutide KwikPen, refrigerated during transit. You inject it subcutaneously, typically into the abdomen or thigh, and from that moment the clock starts on a surprisingly long pharmacological journey.
Semaglutide is absorbed slowly from the injection site. Peak plasma concentration arrives roughly one to three days after the injection. After that, levels decline, but slowly, because the molecule is engineered for extended action. Its elimination half-life sits at around seven days, which means that five half-lives later (roughly 35 days, or five weeks), a single dose has cleared to less than 5% of its peak. In practice, because you inject every week, the drug accumulates. Steady-state blood levels are typically reached after four to five consecutive weekly doses at the same strength. It is at steady state that semaglutide's appetite-reducing and blood-sugar effects are most pronounced, not at the very first injection.
The 0.25mg dose is deliberately low. Its role in the Wegovy titration schedule is to give your gastrointestinal system time to adjust, not to deliver the full weight-management effect. Understanding how long it stays in your body helps explain why nausea often peaks in the first week or two and then eases: as your body reaches steady state, many people find the side effects settle. The Wegovy overview page covers the full titration pathway in more detail.
The seven-day half-life is the same at every dose of Wegovy, it is a property of the semaglutide molecule, not of the specific strength. What changes as you move up the schedule is the absolute amount of drug present at steady state, not the speed at which any given dose clears. The clinical implication: if you stop Wegovy entirely at 0.25mg, the drug is essentially gone within five weeks. If you have been on a higher maintenance dose for months, the same five-week washout applies, but from a higher steady-state baseline, so appetite suppression may linger somewhat longer before fading noticeably.
For a direct comparison with higher strengths, the pharmacokinetics of the 0.5mg step are explored on the how long does 0.5mg Wegovy stay in your system page. The picture at full maintenance is covered in our guide on how long 2.4mg Wegovy stays in the system. If you are interested in what happens after you stop altogether, the clearance timeline after the last dose walks through that in full.
The NHS patient information for semaglutide confirms that the once-weekly injection schedule is designed around this half-life, keeping blood levels stable enough for consistent effect while avoiding the peaks and troughs of daily dosing. You can read the full patient-level summary on the NHS semaglutide medicines page.
Five weeks sounds long. In practical terms, it matters most in three situations: if you need surgery, if you are starting a pregnancy, or if you are weighing up what happens when you stop.
Before any surgical or anaesthetic procedure, your clinical team (including the anaesthetist) should know you are on a GLP-1 medicine. Even at the low 0.25mg starter level, slowed gastric emptying is a relevant consideration. This is standard guidance from NHS England for anyone on weight-management injections, and it applies from the very first dose.
If you are planning to conceive, semaglutide is not recommended during pregnancy. MHRA guidance advises that contraception should be used during treatment; for tirzepatide specifically additional contraception precautions apply during titration, though this is a consideration for those comparing the two medicines. Full details on how these medicines interact with hormonal contraception sit within our weight-loss treatment information.
Thinking about cost while considering whether to continue? Our Wegovy price comparison page sets out what a legitimate private prescription typically includes and how to read the numbers honestly. It is worth a look before making any decision based on price alone.
Stopping at the 0.25mg stage means appetite-suppressing effects wind down gradually over roughly four to five weeks, rather than switching off immediately. Some people find this gentler; others find the slow return of appetite challenging. Either way, any decision to stop, pause or adjust your dose should be made with your prescriber, not unilaterally. The full Wegovy dose guide explains what each step in the titration schedule is trying to achieve.
If you have questions about your specific situation or want to understand whether Wegovy is clinically suitable for you, our prescribers are available to assess you through a free consultation, every application is reviewed by a GPhC-registered Independent Prescriber, not software.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.